MARKET

XLRN

XLRN

Acceleron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

105.03
-6.04
-5.44%
Closed 16:11 09/24 EDT
OPEN
109.82
PREV CLOSE
111.07
HIGH
110.17
LOW
103.80
VOLUME
544.33K
TURNOVER
--
52 WEEK HIGH
112.89
52 WEEK LOW
37.60
MARKET CAP
6.29B
P/E (TTM)
-40.4101
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 21h ago
Acceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) on October 2, 2020
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast for investors and analysts on Friday, October
Business Wire · 09/17 21:01
Acceleron Appoints Laura J. Hamill to its Board of Directors
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Laura J. Hamill to its Board of Directors.
Business Wire · 09/16 11:00
Companies Like Acceleron Pharma (NASDAQ:XLRN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 09/13 15:55
Why Is Acceleron (XLRN) Down 15.1% Since Last Earnings Report?
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 16:31
Hedge Funds Have Never Been This Bullish On Acceleron Pharma (XLRN)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an
Insider Monkey · 09/01 03:35
Acceleron Looks To Next Therapy After Reblozyl Launch
The Reblozyl launch by partner Bristol-Myers Squibb is going well.Sotatercept for Pulmonary Arterial Hypertension reported positive Phase 2 results.The price of the stock is reasonable given longer-term expectations.
Seekingalpha · 08/27 03:53
Acceleron Pharma initiated at strong buy with $155 price target at Raymond James
XLRN | Complete Acceleron Pharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 08/25 12:14
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XLRN. Analyze the recent business situations of Acceleron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XLRN stock price target is 128.85 with a high estimate of 155.00 and a low estimate of 89.00.
EPS
Institutional Holdings
Institutions: 306
Institutional Holdings: 52.02M
% Owned: 86.84%
Shares Outstanding: 59.90M
TypeInstitutionsShares
Increased
90
4.55M
New
79
-10.49K
Decreased
66
4.51M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Independent Director
Francois Nader
President/Chief Executive Officer/Director
Habib Dable
Chief Financial Officer/Senior Vice President/Treasurer
Kevin McLaughlin
Executive Vice President
Jay Backstrom
Executive Vice President
Sujay Kango
Senior Vice President/Chief Scientific Officer
Ravindra Kumar
Senior Vice President
Christopher R. Rovaldi
Director
Laura Hamill
Director
Christopher Hite
Independent Director
Terrence Kearney
Independent Director
Kemal Malik
Independent Director
Thomas McCourt
Independent Director
Karen Smith
Independent Director
Joseph Zakrzewski
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XLRN
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Acceleron Pharma Inc stock information, including NASDAQ:XLRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XLRN stock methods without spending real money on the virtual paper trading platform.